Clinical trial NCT05663749 - References

Schizophrenia — Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics

Citation(s)

•   Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ
  Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999 Nov;156(11):1686-96. doi: 10.1176/ajp.156.11.1686.
•   Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML
  Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008 May 15;32(4):925-31. doi: 10.1016/j.pnpbp.2007.11.013. Epub 2007 Nov 17.
•   DE Hert M, Schreurs V, Vancampfort D, VAN Winkel R
  Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009 Feb;8(1):15-22. doi: 10.1002/j.2051-5545.2009.tb00199.x. Erratum In: World Psychiatry. 2011 Feb;10(1):78.
•   de Silva VA, Suraweera C, Ratnatunga SS, Dayabandara M, Wanniarachchi N, Hanwella R
  Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016 Oct 3;16(1):341. doi: 10.1186/s12888-016-1049-5.
•   Egger C, Muehlbacher M, Schatz M, Nickel M
  Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation. J Clin Psychopharmacol. 2007 Oct;27(5):475-8. doi: 10.1097/jcp.0b013e31814b98e5.
•   Ellinger LK, Ipema HJ, Stachnik JM
  Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. Ann Pharmacother. 2010 Apr;44(4):668-79. doi: 10.1345/aph.1M550. Epub 2010 Mar 16.
•   Flory J, Lipska K
  Metformin in 2019. JAMA. 2019 May 21;321(19):1926-1927. doi: 10.1001/jama.2019.3805.
•   Goh KK, Chen CH, Lu ML
  Topiramate mitigates weight gain in antipsychotic-treated patients with schizophrenia: meta-analysis of randomised controlled trials. Int J Psychiatry Clin Pract. 2019 Mar;23(1):14-32. doi: 10.1080/13651501.2018.1449864. Epub 2018 Mar 20.
•   Ince B, Altinbas K
  [Ten-Year Risk of Cardiovascular Disease in Patients with Bipolar Disorder]. Turk Psikiyatri Derg. 2020 Winter;31(4):225-231. doi: 10.5080/u25270. Turkish.
•   Kay SR, Fiszbein A, Opler LA
  The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-76. doi: 10.1093/schbul/13.2.261.
•   Lawrence D, Hancock KJ, Kisely S
  The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers. BMJ. 2013 May 21;346:f2539. doi: 10.1136/bmj.f2539.
•   Narula PK, Rehan HS, Unni KE, Gupta N
  Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res. 2010 May;118(1-3):218-23. doi: 10.1016/j.schres.2010.02.001. Epub 2010 Mar 7.
•   Praharaj SK, Jana AK, Goyal N, Sinha VK
  Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. Br J Clin Pharmacol. 2011 Mar;71(3):377-82. doi: 10.1111/j.1365-2125.2010.03783.x.
•   Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S
  Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010 Nov;123(2-3):225-33. doi: 10.1016/j.schres.2010.07.012. Epub 2010 Aug 7.
•   Saha S, Chant D, McGrath J
  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007 Oct;64(10):1123-31. doi: 10.1001/archpsyc.64.10.1123.
•   Tang Q, Li X, Song P, Xu L
  Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: Developments in research and prospects for the future. Drug Discov Ther. 2015 Dec;9(6):380-5. doi: 10.5582/ddt.2015.01207.
•   Zheng W, Li XB, Tang YL, Xiang YQ, Wang CY, de Leon J
  Metformin for Weight Gain and Metabolic Abnormalities Associated With Antipsychotic Treatment: Meta-Analysis of Randomized Placebo-Controlled Trials. J Clin Psychopharmacol. 2015 Oct;35(5):499-509. doi: 10.1097/JCP.0000000000000392.

Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial

Details for clinical trial NCT05663749